Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors

Journal of Endourology

Volumn 23, Issue 6, 2009, Pages 977-981

  Geavlete, Bogdan ^a   Multescu, Razvan ^a   Georgescu, Dragos ^a   Geavlete, Petrisor ^a  

^a Saint John Emergency Clinical Hospital   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BLUE LIGHT; CANCER RECURRENCE; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TRANSURETHRAL RESECTION; WHITE LIGHT;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CYSTOSCOPY; FALSE POSITIVE REACTIONS; FEMALE; FLUORESCENCE; HUMANS; MALE; MIDDLE AGED; URETHRA; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 67749111632     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2008.0574     Document Type: Article

References (12)

1. Oosterlinck W, van der Meijden A, et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Guidelines, 2007 edition:1-17.
2. Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: A new approach for bladder cancer detection and surveillance? Eur Urol 2005;47:323-326.
3. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ; PC B302/01 Study Group. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study. J Urol 2007;178:68-73.
4. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301.01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminol-evulinate fluorescence cystoscopy. J Urol 2004;171:135-138.
5. Grossman HB. Improving the management of bladder cancer with fluorescence cystoscopy. J Environ Pathol Toxicol Oncol 2007;26:143-147.
6. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003;170:428-432.
7. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevu-linate fluorescence cystoscopy: A new diagnostic tool for the photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003;170:226-229.
8. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 2005;174:862-866.
9. Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-67.
10. Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: State-of-the-art. Eur Urol 2008;53:1138-1148.
11. DenzingerS,BurgerM,WalterB,KnuechelR,Roessler W, Wieland WF, Filbeck T. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007;69:675-679.
12. Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174:2129-2133.